New electrochemiluminescent immunoassay for the determination of CYFRA 21- 1: Analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer

Clinical Chemistry

Volumn 45, Issue 11, 1999, Pages 1944-1953

  Sánchez Carbayo, Marta ^a   Espasa, Antonia ^a   Chinchilla, Virtudes ^a   Herrero, Enrique ^a   Megías, Julián ^a   Mira, Antonio ^a   Soria, Federico ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT;

ARTICLE; BLADDER CANCER; CHEMOLUMINESCENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ELECTROIMMUNOASSAY; EVALUATION; HUMAN; REGRESSION ANALYSIS; URINALYSIS;

EID: 0032714293     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.11.1944     Document Type: Article

References (29)

1. 1. Fuchs E. Keratins as biochemical markers of epithelial differentiation. Trends Genet 1988;4:277-81.
2. 2. Bodenmüller H. The biochemistry of CYFRA 21.1 and other
3. 3. Rastel D. Measurement of cytokeratin 19 fragments in serum: clinical application of a tumor marker called CYFRA21-1. Tumor Marker Update 1995;7:55-63.
4. 4. Molina R, Agusti C, Filella X, Jo J, Joseph J, Giménez N, Ballesta AM. Study of a new tumor marker, CYFRA21-1, in malignant and nonmalignant diseases. Tumor Biol 1994;15:318-25.
5. 5. Giovanella L, Ceriani L, Bandera M, Beghe B, Roncari G. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21-1 in lung cancer. Int J Biol Markers 1995;3:156-60.
6. 6. Molina R, Agustí C, Mané JM, Filella X, Jo J, Joseph J. et al. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;2:96-101.
7. 7. Stieber P, Schmeller N, Schambeck CH, Hofmann K, Reiter W, Hasholzner U, Fateh-Moghadam A. Clinical relevance of CYFRA 211, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Anticancer Res 1996;16:3793-8.
8. 8. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 1982:31:11-24.
9. 9. Raghaven D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. New Engl J Med 1990;322:1129-35.
10. 10. Griffiths L, Neal DE. Prognostic markers in bladder cancer. Curr Opin Urol 1996;6:267-71.
11. 11. Newling DW. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol 1996;6:272-5.
12. 12. Javle M, Raghavan D. Progress in the treatment of invasive bladder cancer. Curr Opin Urol 1996;6:280-5.
13. 13. Morris SB, Gordon EM, Shearer RJ, Woodhouse CR. Superficial bladder cancer: for how long should a tumor-free patient have check cystoscopies? Br J Urol 1995;75:193-6.
14. 14. Badalament RA, Harmansen DK, Kimmel M, Gay H, Herr HW, Fair WR, et al. The sensitivity of bladder cancer wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987;60:1423-7.
15. 15. Cordon-Cardo C, Wartinger DD, Melamed MR, Fair W, Fradet Y. Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low grade superficial bladder tumors. Am J Pathol 1992;140:375-80.
16. 16. Sarosdy MF, de Vere White RW, Soloway MS, Shienfeld J, Hudson MA, Schellhammer PF, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379-84.
17. 17. Soloway MS, Briggman JV, Carpinito GA, Choda, GW, Church PA, Lamm DL, et al. Use a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156: 363-7.
18. 18. Schmetter BS, Habitch KK, Lamm DL, Morales A, Bander NH, Grossmaan HB, et al. A multicenter trial evaluation of the fibrin/ fribrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997;158:801-5.
19. 19. Sánchez-Carbayo M, Herrero E, Megías J, Espasa A, Chinchilla V, Mira A, Soria F. Initial evaluation of UBC as a tumor marker for bladder cancer. J Urol 1999;161:1110-5.
20. 20. European Committee for Clinical Laboratory Standards. Guidelines for the evaluation of analyzers in clinical chemistry. ECCLS Document, Vol. 3, No. 2. Berlin: Beuth Verlag, 1986.
21. 4 estimate or sensitive TSH measurement. J Clin Immunoassay 1989;12:82-9.
22. 22. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices. NCCLS Document EP5-T2. Villanova, PA: NCCLS, 1992.
23. 23. Broughton PMG, Gowenlock AH, McCormack JJ, Neill DW. A revised scheme for the evaluation of automatic instruments for use in clinical chemistry. Ann Clin Biochem 1974;11:207-18.
24. 24. Dittadi R, Barioli P, Gion M, Mione R, Barichello M, Capitanio G, et al. Standardization of assay for cytokeratin-related tumor marker CYFRA 21-1 in urine samples. Clin Chem 1996;42:1634-8.
25. 25. Bodenmuller H, Banauch D, Ofenloch B, Jaworek D, Dessauer A. Technical evaluation of a new automated tumor marker assay: the Enzymun-Test CYFRA 21-1. In: Klapdor R, ed. Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Munich: Zuckschwerdt Verlag, 1992:137-8
26. 26. Kroll MH, Ellin RJ. Interference with clinical laboratory analyses. Clin Chem 1994;40:1996-2005.
27. 27. Bodenmuller H, Donié F, Kaufmann M, Banauch D. The tumor marker TPA, TPS TPA cyK and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 1994;9:70-4.
28. 28. Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, Le Guillou M, Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997;158:338-41.
29. 29. Ooms EC, Anderson WA, Alons CL, Boon ME, Veldhuizen RW. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 1993;14:140-2.